EP1019427A4 - N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators - Google Patents
N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulatorsInfo
- Publication number
- EP1019427A4 EP1019427A4 EP98939156A EP98939156A EP1019427A4 EP 1019427 A4 EP1019427 A4 EP 1019427A4 EP 98939156 A EP98939156 A EP 98939156A EP 98939156 A EP98939156 A EP 98939156A EP 1019427 A4 EP1019427 A4 EP 1019427A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- adenosine
- uronamides
- substituted
- receptor modulators
- adenosine receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5406497P | 1997-07-29 | 1997-07-29 | |
US54064P | 1997-07-29 | ||
PCT/US1998/016053 WO1999006053A1 (en) | 1997-07-29 | 1998-07-29 | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1019427A1 EP1019427A1 (en) | 2000-07-19 |
EP1019427A4 true EP1019427A4 (en) | 2000-07-19 |
Family
ID=21988552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98939156A Withdrawn EP1019427A4 (en) | 1997-07-29 | 1998-07-29 | N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1019427A4 (en) |
JP (1) | JP2003517423A (en) |
AU (1) | AU8764398A (en) |
CA (1) | CA2296485A1 (en) |
WO (1) | WO1999006053A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU750322B2 (en) * | 1997-05-09 | 2002-07-18 | Trustees Of The University Of Pennsylvania, The | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IL139787A0 (en) | 1998-06-02 | 2002-02-10 | Osi Pharm Inc | PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE |
IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
PT1246623E (en) | 1999-12-02 | 2006-12-29 | Osi Pharm Inc | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
AU2002211142A1 (en) * | 2000-10-26 | 2002-05-06 | Actar Ab | Screening method using a g coupled receptor associated with a specific g protein |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IL156704A0 (en) * | 2001-01-16 | 2004-01-04 | Can Fite Biopharma Ltd | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
CA2468673C (en) | 2001-11-30 | 2011-01-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 and a3 receptors and uses thereof |
CN1816551A (en) | 2001-12-20 | 2006-08-09 | Osi药物公司 | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
ATE458483T1 (en) | 2001-12-20 | 2010-03-15 | Osi Pharm Inc | SELECTIVE PYRIMIDINE A2B ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
JP2007514647A (en) * | 2003-10-21 | 2007-06-07 | インスパイアー ファーマシューティカルズ,インコーポレイティド | Tetrahydro-furo [3,4-d] dioxole compounds and compositions and methods for inhibiting platelet aggregation |
EP1778239B1 (en) * | 2004-07-28 | 2013-08-21 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
EP1798233A1 (en) * | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
PL2227234T3 (en) | 2007-10-15 | 2014-11-28 | Can Fite Biopharma Ltd | Method for inducing hepatocyte proliferation and uses thereof |
MX2011012229A (en) | 2009-05-17 | 2011-12-08 | Can Fite Biopharma Ltd | A3 adenosine receptor agonists for the reduction of intraocular pressure. |
EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
US20130045943A1 (en) | 2010-03-03 | 2013-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | A3ar agonists for the treatment of uveitis |
WO2014024195A1 (en) | 2012-08-09 | 2014-02-13 | Can-Fite Biopharma Ltd. | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction |
IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
IL254535A0 (en) | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for managing cytokine release syndrome |
IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050047A1 (en) * | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
-
1998
- 1998-07-29 CA CA002296485A patent/CA2296485A1/en not_active Abandoned
- 1998-07-29 JP JP2000504866A patent/JP2003517423A/en active Pending
- 1998-07-29 AU AU87643/98A patent/AU8764398A/en not_active Abandoned
- 1998-07-29 EP EP98939156A patent/EP1019427A4/en not_active Withdrawn
- 1998-07-29 WO PCT/US1998/016053 patent/WO1999006053A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050047A1 (en) * | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
Non-Patent Citations (3)
Title |
---|
C.GALLO-RODRIGUEZ ET AL.: "Structure Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3 Selective Adenosine Agonists.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 5, 4 March 1994 (1994-03-04), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 636 - 646, XP002136400, ISSN: 0022-2623 * |
H.O.KIM ET AL.: "2-Substitution of N6-Benzoyladenosine-5'-Uronamides Enhances Selectivity for A3 Adenosine Receptors.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 21, 14 October 1994 (1994-10-14), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 3614 - 3621, XP002136401, ISSN: 0022-2623 * |
See also references of WO9906053A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2296485A1 (en) | 1999-02-11 |
JP2003517423A (en) | 2003-05-27 |
EP1019427A1 (en) | 2000-07-19 |
AU8764398A (en) | 1999-02-22 |
WO1999006053A1 (en) | 1999-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1019427A4 (en) | N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators | |
GB2353527B (en) | Adenosine A3 receptor modulators | |
HUP0100536A3 (en) | Fiber distributor | |
GB9715751D0 (en) | Formulations | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
EP0996458A4 (en) | Sandramycin analogs | |
IL133920A0 (en) | Trail receptor | |
AU7132898A (en) | Edg-1-like receptor | |
GB9517098D0 (en) | Receptor | |
GB9617923D0 (en) | Novel receptor | |
EP0973800A4 (en) | Novel receptor | |
GB2321753B (en) | Metering system | |
PL340723A1 (en) | Structural member | |
GB9701050D0 (en) | Structural member | |
GB9515669D0 (en) | Releasable fixing means | |
PL320747A1 (en) | Novel receptor | |
ZA987267B (en) | Nucleosides | |
IL139493A0 (en) | Adenosine a3 receptor modulators | |
IL156851A0 (en) | Adenosine a3 receptor modulators | |
GB9703676D0 (en) | Stable system | |
GB9810606D0 (en) | Distributor units | |
HU0002453D0 (en) | Novel nucleosides | |
CA81596S (en) | Structural member | |
AU133746S (en) | Distributor | |
AUPO910797A0 (en) | Receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000202 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000606 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010330 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011010 |